# A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

> **NCT01414855** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** obinutuzumab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin
- **DRUG:** prednisone
- **DRUG:** vincristine

## Key facts

- **NCT ID:** NCT01414855
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-31
- **Primary completion:** 2013-12-31
- **Final completion:** 2016-12-23
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2018-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01414855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01414855, "A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01414855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*